SARS-CoV-2 Hangi Dokularda Patolojiye Neden Oluyor?

Yıl 2023, Cilt: 18 Sayı: 3, 110 - 116, 20.11.2023

Müzeyyen Izmirli

https://doi.org/10.17517/ksutfd.1163335

Öz

COVID-19 pandemi süreci Aralık 2019’da Çin’de başlamıştır. COVID-19 hastalığına neden olan virüs SARS-CoV-2’dir ve mutasyon geçirmeye devam ederek kendi alt türlerini oluşturmaktadır. Çin'de ve dünya genelinde vaka sayısındaki hızlı artış nedeniyle DSÖ, 11 Mart 2020'de SARS-CoV-2’nin neden olduğu COVID-19 hastalığı için, pandemi ilan etmiştir. SARS-CoV-2 özellikle akciğer parankimini etkilemekte ve etkilenen hastalar, asemptomatik enfeksiyonlardan ölümle sonuçlanan ciddi süreçlere kadar çeşitli klinik belirtiler gösterebilmektedir. Ayrıca, COVID-19 hastalarında en çok solunum tutulumu görülmekte, ancak virüs diğer organ sistemlerini de etkileyebilmektedir. Virüsün hücrelere girerken bir kapı gibi kullandığı reseptör ACE2’dir ve birçok hücre tipinde eksprese olmaktadır. Bu nedenle de virüs sistemik inflamasyon ile gastrointestinal, kardiyovasküler, hematolojik, renal, kas-iskelet, nöroloji, üriner ve üreme sisteminde dokulara hasar vermektedir.
Sonuç olarak, SARS-COV-2, halen alt tipleri ile etkisini devam ettirmektedir. SARS-CoV-2’nin farklı hücrelerde ve dokularda neden olduğu hasarın erken teşhis edilmesi ve tedavi seçeneklerinin erken uygulanmaya başlanması faydalı olacaktır.

Anahtar Kelimeler

SARS-CoV-2, COVID-19, ACE2 reseptörü, COVID-19 patolojileri

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

yok

In Which Tissues Does SARS-CoV-2 Cause Pathology?

Öz

The COVID-19 pandemic process started in China in December 2019. The virus is SARS-CoV-2 that causes COVID-19 disease and SARS-CoV-2 continues to mutate, forming its own subspecies. Due to the rapid increase in the number of cases in China and worldwide, WHO declared a pandemic on 11 March 2020 for the COVID-19 disease caused by SARS-CoV-2. SARS-CoV-2 particularly affects the lung parenchyma, and affected patients may present with clinical manifestations ranging from asymptomatic infections to severe processes resulting in death. Moreover, respiratory involvement is most common in COVID-19 patients, but the virus can also affect other organ systems. The receptor that is ACE2 is used like a gate for the virus when entering cells and is expressed in many cell types. For this reason, the virus damages many tissues such as gastrointestinal, cardiovascular, hematological, renal, musculoskeletal, neurology, urinary and reproductive systems with systemic inflammation.
As a result, SARS-CoV-2 still continues its effect with its subtypes. Early diagnosis of the damage caused by SARS-CoV-2 in different cells and tissues and early application of treatment options will be beneficial.

Anahtar Kelimeler

SARS-CoV-2, COVID-19, ACE2 receptor, The pathologies of COVID-19

Proje Numarası

yok

Kaynakça

• Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus Disease (COVID-19): Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front Public Health. 2021;8:582932.
• Büdün Aydın E, Aydın A. A Critical Analysis of the Discourses Developed by the World Health Organization at the Beginning of the Covid-19 Pandemic. Afyon Kocatepe University Journal of Social Sciences. 2022;24(2):521-537.
• COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. The Lancet. 2022;10334(399):1513-1536.
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
• Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Encyclopedia of Virology. 2021;428-440.
• Hikmet F, Méar L, Edvinsson A, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610.
• Wang D, Hu B, Hu C. Clinical Characteristics of 138 Hospitalized Patients with2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
• Varga Z, Flammer AJ, Steiger P. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395:1417-1418.
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
• Amirfakhryan H, Safari F. Outbreak of SARS-CoV-2: Pathogenesis of infection and cardiovascular involvement. Hellenic J Cardiol. 2021;62(1):13-23.
• Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-25.
• McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, et al. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol. 2021;75(3):647-658.
• Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-678.
• Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. Liver Int. 2021;41(9):1988-1998.
• Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterol. 2020;159(1):367-70.
• McNabb‐Baltar J, Jin DX, Grover AS, Redd WD, Zhou JC, Hathorn KE, et al. Lipase elevation in patients with COVID‐19. Am J Gastroenterol. 2020;115 (8):1286-8.
• Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, et al. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J. 2021;9(7):750-765.
• Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997-1001.
• Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterol. 2020;159(1):81-95.
• Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg. 2021;115(12):1362-1388.
• Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022;226(2):177-186.
• Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193:E540-E548.
• Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19) Obstet Gynecol. 2021;137:571-580.
• Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175:817-826.
• Yang M, Chen S, Huang B, Zhong JM, Su H, Chen YJ, et al. Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications. Eur Urol Focus. 2020;6(5):1124-1129.
• Ma X, Guan C, Chen R, Wang Y, Feng S, Wang R, et al. Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. Cell Mol Immunol. 2021;18(2):487-489.
• Çayan S, Uğuz M, Saylam B, Akbay E. Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study. Aging Male. 2020;23:1493-1503.
• Ardestani Zadeh A, Arab D. COVID-19 and male reproductive system: pathogenic features and possible mechanisms. J Mol Histol. 2021;52(5):869-878.
• Şit D, Kayabaşı H. SARS-CoV-2 ile İlişkili Akut Böbrek Hasarı. Dicle Tıp Derg. 2020:47(2):498-507.
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
• Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3-19.
• Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690.
• Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun. 2020;87:33.
• Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurol. 2020;95(5):e601-e605.
• Cipollaro L, Giordano L, Padulo J, Oliva F, Maffulli N. Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients. J Orthop Surg Res. 2020;15(1):178.
• Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Neck Surg. 2020;163:3-11.
• Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
• Al-Namaeh M. Ocular manifestations of COVID-19. Therapeutic Advances in Ophthalmol. 2022;14. doi:10.1177/25158414221083374
• Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P, Fernández-Nieto D, Lario AR-V, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183:71-7.
• Tang K, Wang Y, Zhang H, Zheng Q, Fang R, Sun Q. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review. Dermatol Ther. 2020;33:e13528.